Sina Vatandoust1, Timothy J Price2, Shahid Ullah3, Amitesh C Roy4, Carole Beeke5, Joanne P Young6, Amanda Townsend2, Robert Padbury7, David Roder8, Christos S Karapetis4. 1. Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia; Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia. Electronic address: Sina.Vatandoust@health.sa.gov.au. 2. Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; The University of Adelaide, Adelaide, South Australia, Australia. 3. Flinders Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University, Adelaide, South Australia, Australia. 4. Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia; Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia. 5. Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia. 6. The University of Adelaide, Adelaide, South Australia, Australia; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia. 7. Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia; Department of Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia. 8. University of South Australia, Adelaide, South Australia, Australia.
Abstract
BACKGROUND: Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 years of age at the time of diagnosis of metastatic disease. To our knowledge this is the first study to focus on this age group with mCRC. PATIENTS AND METHODS: This was a retrospective study using data from the South Australian Metastatic Colorectal Cancer database. We compared patient and disease characteristics, management approaches, and outcomes for age groups < 40 and ≥ 40. A multivariate Cox proportional hazards model was fitted to compare the survival outcomes (death from all causes) between the 2 groups. RESULTS: From 3318 patients, 46 (1.4%) were younger than 40 years of age. In a comparison of patients in the younger than 40-year-old group with the older group, a greater proportion had synchronous metastatic disease (80.4% vs. 64.4%, respectively; P = .04) and disease originating from the left colon (71.7% vs. 61.7%, respectively; P = .035); also a larger proportion in the younger than 40-year-old group received chemotherapy compared with the older group (82.6% vs. 58.7%, respectively; P < .01). In the adjusted multivariate model, survival was not significantly different between the 2 groups (hazard ratio, 0.81; 95% confidence interval, 0.56-1.16; log rank P = .25). CONCLUSION: Young-onset mCRC patients, when defined as aged younger than 40 years, have equivalent survival compared with their older counterparts. This is despite differences in disease characteristics and management approach between the 2 groups.
BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 years of age at the time of diagnosis of metastatic disease. To our knowledge this is the first study to focus on this age group with mCRC. PATIENTS AND METHODS: This was a retrospective study using data from the South Australian Metastatic Colorectal Cancer database. We compared patient and disease characteristics, management approaches, and outcomes for age groups < 40 and ≥ 40. A multivariate Cox proportional hazards model was fitted to compare the survival outcomes (death from all causes) between the 2 groups. RESULTS: From 3318 patients, 46 (1.4%) were younger than 40 years of age. In a comparison of patients in the younger than 40-year-old group with the older group, a greater proportion had synchronous metastatic disease (80.4% vs. 64.4%, respectively; P = .04) and disease originating from the left colon (71.7% vs. 61.7%, respectively; P = .035); also a larger proportion in the younger than 40-year-old group received chemotherapy compared with the older group (82.6% vs. 58.7%, respectively; P < .01). In the adjusted multivariate model, survival was not significantly different between the 2 groups (hazard ratio, 0.81; 95% confidence interval, 0.56-1.16; log rank P = .25). CONCLUSION: Young-onset mCRC patients, when defined as aged younger than 40 years, have equivalent survival compared with their older counterparts. This is despite differences in disease characteristics and management approach between the 2 groups.
Authors: Mohamed E Salem; Francesca Battaglin; Richard M Goldberg; Alberto Puccini; Anthony F Shields; David Arguello; W Michael Korn; John L Marshall; Axel Grothey; Heinz-Josef Lenz Journal: Oncologist Date: 2019-12-17
Authors: Jeremy R Burt; Jeffrey Waltz; Ashley Ramirez; Andres Abadia; Basel Yacoub; Sydney A Burt; Fiona Tissavirasingham; Madison R Kocher Journal: Abdom Radiol (NY) Date: 2020-09-16
Authors: Alberto Puccini; Heinz-Josef Lenz; John L Marshall; David Arguello; Derek Raghavan; W Michael Korn; Benjamin A Weinberg; Kelsey Poorman; Arielle L Heeke; Philip A Philip; Anthony F Shields; Richard M Goldberg; Mohamed E Salem Journal: Oncologist Date: 2018-07-17
Authors: Fanny E R Vuik; Stella A V Nieuwenburg; Iris D Nagtegaal; Ernst J Kuipers; Manon C W Spaander Journal: Aliment Pharmacol Ther Date: 2021-10-12 Impact factor: 9.524
Authors: Stephanie Wong; Ilmars Lidums; Christophe Rosty; Andrew Ruszkiewicz; Susan Parry; Aung Ko Win; Yoko Tomita; Sina Vatandoust; Amanda Townsend; Dainik Patel; Jennifer E Hardingham; David Roder; Eric Smith; Paul Drew; Julie Marker; Wendy Uylaki; Peter Hewett; Daniel L Worthley; Erin Symonds; Graeme P Young; Timothy J Price; Joanne P Young Journal: BMC Gastroenterol Date: 2017-04-19 Impact factor: 3.067
Authors: Hyehyun Jeong; Eunjung Lee; Deokhoon Kim; Jihun Kim; Sun Young Kim; Yong Sang Hong; Tae Won Kim; Jeong Eun Kim Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 3.302